Large prospective studies are required to validate whether immunohistochemical expression of BCL-xL, BCL-2, and MCL-1 in pre-treatment biopsy specimens on patients with HNSCC is associated with response to radiation/chemoradiation. The gene discussed is BCL2; the disease is head and neck squamous cell carcinoma.